Prion removal capacity of plasma protein manufacturing processes: A data collection from PPTA member companies

Transfusion

Volumn 53, Issue 9, 2013, Pages 1894-1905

  Cai, Kang ^a   Gröner, Albrecht ^a   Dichtelmüller, Herbert O ^a   Fabbrizzi, Fabrizio ^a   Flechsig, Eckhard ^a   Gajardo, Rodrigo ^a   Von Hoegen, Ilka ^a   Jorquera, Juan I ^a   Kempf, Christoph ^a   Kreil, Thomas R ^a   Lee, Douglas C ^a   Moscardini, Mila ^a   Pölsler, Gerhard ^a   Roth, Nathan J ^a  

^a Baxter R and D Europe   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; COLD ETHANOL; OCTANOIC ACID; PLASMA PROTEIN; PRION PROTEIN; UNCLASSIFIED DRUG;

ADSORPTION CHROMATOGRAPHY; AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CAPRYLATE PRECIPITATION; CHEMICAL ANALYSIS; CRYOPRECIPITATION; FILTRATION; INFORMATION PROCESSING; ION EXCHANGE CHROMATOGRAPHY; MEDICAL SOCIETY; NANOFILTRATION; NONHUMAN; PH; PRECIPITATION; PRION; REPRODUCIBILITY; SALT PRECIPITATION; VIRUS INFECTIVITY;

BLOOD PROTEINS; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, ION EXCHANGE; CREUTZFELDT-JAKOB SYNDROME; DRUG CONTAMINATION; FILTRATION; HUMANS; PRIONS;

EID: 84883886316     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12050     Document Type: Article

References (49)

1. Prusiner SB,. Prions. Proc Natl Acad Sci U S A 1998; 95: 13363-13383.
2. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge J, Doey LJ, Lantos P,. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448-450.
3. Turner ML, Ludlam CA,. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009; 144: 14-23.
4. Peden A, McCardle L, Head MW, Love S, Ward HJ, Cousens SN, Keeling DM, Millar CM, Hill FG, Ironside JW,. Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16: 296-304.
5. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ,. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999-1000.
6. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F,. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83 (Pt 11): 2897-2905.
7. McCutcheon S, Alejo Blanco AR, Houston EF, de, Wolf C, Tan BC, Smith A, Groschup MH, Hunter N, Hornsey VS, MacGregor IR, Prowse CV, Turner M, Manson JC,. All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD. PLoS ONE 2011; 6: e23169.
8. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J,. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703-704.
9. Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG,. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 2004; 364: 529-531.
10. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN,. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38: 810-816.
11. Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohan WN, Brown P,. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003; 43: 1687-1694.
12. Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC, Carbonell RG, Burton SJ, Hammond DJ, Rohwer RG,. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selected affinity resins. Lancet 2006; 368: 2232-2236.
13. Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan WN,. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39: 1169-1178.
14. Comer PJ,. Risk assessment of exposure to vCJD infectivity in blood and blood products for the Department of Health of United Kingdom. London: DNV Consulting; 2003.
15. Gregori L, Yang H, Anderson S,. Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion 2011; 51: 2596-2602.
16. National CJD Research & Surveillance Unit. vCJD statistics by the National Creutzfeldt-Jakob Disease Research & Surveillance Unit. 2012. [cited 2012 Sep 10]. Available from: URL: http://www.cjd.ed.ac.uk/
17. European Creutzfeldt Jakob Disease Surveillance Network. vCJD statistics by European Creutzfeldt Jakob Disease Surveillance Network. 2012. [cited 2012 Sep 10]. Available from: URL: http://www.eurocjd.ed.ac.uk/
18. Collins SJ, Lawson VA, Masters CL,. Transmissible spongiform encephalopathies. Lancet 2004; 363: 51-61.
19. US Food and Drug Administration. Guidance for industry, revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products. May 2010.
20. Committee for Medicinal Products for Human. Use (CHMP) position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products. June 2011, EMA/CHMP/BWP/303353/2010.
21. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC,. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 2000; 78: 86-95.
22. Foster PR, Griffin BD, Bienek C, McIntosh RV, MacGregor IR, Somerville RA, Steele PJ, Reichl HE,. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang 2004; 86: 92-99.
23. Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JL, Gilligan KJ, Rubenstein R, Fournel M, Petteway SR Jr,. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 2000; 84: 77-89.
24. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr,. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 2001; 41: 449-455.
25. Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC, Li H, Petteway S, Remington KM,. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003; 84: 176-187.
26. Reichl HE, Foster PR, Welch AG, Li Q, MacGregor IR, Somerville RA, Fernie K, Steele PJ, Taylor DM,. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang 2002; 83: 137-145.
27. Van Holten RW, Autenrieth SM,. Evaluation of depth filtration to remove prion challenge from an immune globulin preparation. Vox Sang 2003; 85: 20-24.
28. Cai K, Miller JL, Stenland CJ, Gilligan KJ, Hartwell RC, Terry JC, Evans-Storms RB, Rubenstein R, Petteway SR Jr, Lee DC,. Solvent-dependent precipitation of prion protein. Biochim Biophys Acta 2002; 1597: 28-35.
29. Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG,. Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 2004; 32: 1-10.
30. Vey M, Baron H, Weimer T, Gröner A,. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals 2002; 30: 187-196.
31. Flan B, Arrabal S,. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal. Transfus Clin Biol 2007; 14: 51-62.
32. Thyer J, Unal A, Thomas P, Eaton B, Bhashyam R, Ortenburg J, Uren E, Middleton D, Selleck P, Maher D,. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins. Vox Sang 2006; 91: 292-300.
33. Yunoki M, Urayama T, Ikuta K,. Possible removal of prion agents from blood products during the manufacturing process. Future Virol 2006; 1: 659-674.
34. Stucki M, Boschetti N, Schäfer W, Hostettler T, Käsermann F, Nowak T, Gröner A, Kempf C,. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008; 36: 239-247.
35. Diez JM, Caballero S, Belda FJ, Otegui M, Gajardo R, Jorquera JI,. Elimination capacity of a TSE-model agent in the manufacturing process of Alphanate/Fanhdi, a human factor VIII/VWF complex concentrate. Haemophilia 2009; 15: 1249-1257.
36. Diez JM, Caballero S, Belda F, Otegui M, Gajardo R, Jorquera JI,. Capacity of the manufacturing process of Flebogamma(®) DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agent. Biologicals 2010; 38: 670-674.
37. Stenland CJ, Lee DC, Brown P, Petteway SR Jr, Rubenstein R,. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion 2002; 42: 1497-1500.
38. Committee for Proprietary Medicinal Products. Guideline on the investigation of manufacturing processes for plasma-derived medicinal products with regard to vCJD risk. October 2004, EMEA/CPMP/BWP/5136/03.
39. Bellon A, Seyfert-Brandt W, Lang W, Baron H, Gröner A, Vey M,. Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity. J Gen Virol 2003; 84 (Pt 7): 1921-1925.
40. Prusiner SB, Tremblay P, Safar J, Torchia M, DeArmond SJ,. Bioassay of prions. In:, Prusiner SB, editor. Prion biology and diseases. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1999. p. 119.
41. Committee for Proprietary Medicinal Products. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. February 1996. (Revised) (CPMP/BWP/268/95).
42. Cohn EJ, Strong LE, Hughes WL Jr., Mulford DJ, Ashworth JN, Melin M, Taylor HL,. Preparation and properties of serum and plasma proteins III. System for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68: 459-475.
43. Kistler P, Nitschmann H,. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 1962; 7: 414-424.
44. Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, Alpers MP,. Kuru in the 21st century-an acquired human prion disease with very long incubation periods. Lancet 2006; 367: 2068-2074.
45. Prusiner SB, McKinley MP, Groth DF, Bowman KA, Mock NI, Cochran SP, Masiarz FR,. Scrapie agent contains a hydrophobic protein. Proc Natl Acad Sci U S A 1981; 78: 6675-6679.
46. Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, Groth DF, Glenner GG,. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 1983; 35 (2 Pt 1): 349-358.
47. Callahan MA, Xiong L, Caughey B,. Reversibility of scrapie-associated prion protein aggregation. J Biol Chem 2001; 276: 28022-28028.
48. Meyer RK, McKinley MP, Bowman KA, Braunfeld MB, Barry RA, Prusiner SB,. Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci U S A 1986; 83: 2310-2314.
49. Wille H, Prusiner SB,. Ultrastructural studies on scrapie prion protein crystals obtained from reverse micellar solutions. Biophys J 1999; 76: 1048-1062.